Stereoselective neuroprotection by novel 2,3-benzodiazepine non- competitive AMPA antagonists against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures

Neuroscience Letters

Volumn 262, Issue 3, 1999, Pages 219-221

  May, Patrick C ^a   Robison, Paula M ^a   Fuson, Kimberly S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Amino 3 hydroxy 5 methyl isoxazolepropionate kainic acid receptor; Excitotoxicity; GYKI 52466; Kainate; LY300164; LY303070; Rat hippocampal culture

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; CYCLOTHIAZIDE; EXCITOTOXIN; FLUMAZENIL; GLUTAMIC ACID; KAINIC ACID; LACTATE DEHYDROGENASE; LY 303071; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; FETUS; HIPPOCAMPUS; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; STEREOISOMERISM;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BENZODIAZEPINES; CELL SURVIVAL; CELLS, CULTURED; EXCITATORY AMINO ACID ANTAGONISTS; FETUS; FLUMAZENIL; HIPPOCAMPUS; KAINIC ACID; L-LACTATE DEHYDROGENASE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033548643     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00084-1     Document Type: Article

References (17)

1. Bleakman D., Ballyk B., Schoepp D., Palmer A., Bath C., Sharpe E., Woolley M., Bufton H., Kamboj R., Tarnawa I., Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35:1996;1689-1702.
2. Choi D.W. Glutamate receptors and the induction of excitotoxic neuronal death. Prog. Brain Res. 100:1994;47-51.
3. Ehlert F., Ragan P., Chen A., Roeske W., Yamamura H. Modulation of benzodiazepine receptor binding: Insight into pharmacologic efficacy. Eur. J. Pharmacol. 78:1982;249-253.
4. Fletcher E., Lodge D. New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol. Ther. 70:1996;65-89.
5. Gill R., Lodge D. Pharmacology of AMPA antagonists and their role in neuroprotection. Int. Rev. Neurobiol. 40:1997;197-232.
6. Koh J.-Y., Goldberg M.P., Hartley D.M., Choi D.W. Non-NMDA receptor mediated neurotoxicity in cortical culture. J. Neurosci. 10:1990;693-705.
7. Kovacs A., Szabo G. GYKI 53655, a 2,3 benzodiazepine, non-competitively protects cultures neurones against AMPA toxicity. Eur. J. Pharmacol. 331:1997;93-96.
8. Lees K. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:1997;S66-S69.
9. Liu X.-H., Wang P., Barks J.D.E. The non-competitive AMPA antagonist LY300168 (GYKI 53655) attenuates AMPA-induced hippocampal injury in neonatal rodents. Neurosci. Lett. 235:1997;93-97.
10. Lodge D., Bond A., O'Neill M., Hicks C., Jones M. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology. 35:1996;1681-1688.
11. May P., Robison P. Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures. J. Neurochem. 60:1993;1171-1174.
12. May P., Robison P. GYKI 52466 protects against non-NMDA receptor mediated excitotoxicity in primary rat hippocampal cultures. Neurosci. Lett. 152:1993;169-172.
13. Ohno K., Okada M., Tsutsumi R., Matsumoto N., Yamaguchi T. Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures. Neurochem. Int. 32:1998;265-271.
14. Rogawski M. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
15. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 18:1995;57-58.
16. Summer B., Seeburg P.H. Glutamate receptor channels: novel properties and new clones. Trends Pharmacol. Sci. 13:1992;291-296.
17. Vizi E., Mike A., Tarnawa I. 2,3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Reviews. 2:1996;91-126.